1. Volume 3, Issue 2, Pages 185-197 (February 2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma 
Andreas Rosenwald, George Wright, Adrian Wiestner, Wing C Chan, Joseph M Connors, Elias Campo, Randy D Gascoyne, Thomas M Grogan, H.Konrad Muller-Hermelink, Erlend B Smeland, Michael Chiorazzi, Jena M Giltnane, Elaine M Hurt, Hong Zhao, Lauren Averett, Sarah Henrickson, Liming Yang, John Powell, Wyndham H Wilson, Elaine S Jaffe, Richard Simon, Richard D Klausner, Emilio Montserrat, Francesc Bosch, Timothy C Greiner, Dennis D Weisenburger, Warren G Sanger, Bhavana J Dave, James C Lynch, Julie Vose, James O Armitage, Richard I Fisher, Thomas P Miller, Michael LeBlanc, German Ott, Stein Kvaloy, Harald Holte, Jan Delabie, Louis M Staudt 
Cancer Cell 
Volume 3, Issue 2, Pages (February 2003)
DOI: /S (03)00028-X

2. Figure 1 Molecular diagnosis of mantle cell lymphoma
A: Hierarchical clustering of expression measurements from 42 MCL signature genes that are more highly expressed in 92 MCL samples than in 20 SLL, 83 ABC LBCL, and 134 GCB DLBCL samples (see text for details). Each column represents a single lymphoma specimen, and each row represents expression of a single gene. Red squares indicate increased expression and green squares indicate decreased expression relative to the median expression level according to the color scale shown. The right panel shows the median gene expression for the 42 MCL signature genes in each of the lymphoma subgroups.
B: Performance of the gene expression-based diagnostic test for MCL in each of the three models (MCL versus ABC DLBCL, MCL versus GCB DLBCL, and MCL versus SLL) in the “training set” and in the “validation set” of cases.
C: Expression of MCL signature genes in seven cyclin D1-positive and seven cyclin D1-negative lymphoma cases. Cyclin D1-negative cases had MCL morphology and immunophenotype and were classified as MCL based on their gene expression profile. Shown below is the relative gene expression of cyclin D1 (as measured by quantitative RT-PCR) and cyclins D2 and D3 (as measured by DNA microarray analysis).
D: Kaplan-Meier estimates of overall survival of patients with cyclin D1-positive and cyclin D1-negative MCL.
Cancer Cell 2003 3, DOI: ( /S (03)00028-X)

3. Figure 2 A gene expression-based predictor of survival
A: Relative expression of 20 proliferation signature genes that were used to compute the proliferation signature average. Cyclin D1-positive MCL cases are ordered according to their expression of the proliferation signature average. The color scale depicts gene expression over a 4-fold range.
B: Kaplan-Meier plots of overall survival according to a survival predictor based on the proliferation signature average. Separate plots are shown for patients in the training set and the validation set and for all patients combined. For visualization, patients were ranked according to their proliferation signature average and divided into 4 equal quartiles.
Cancer Cell 2003 3, DOI: ( /S (03)00028-X)

4. Figure 3
Proliferation and survival rates in different histological subtypes of MCL
A: Proliferation signature averages in the classic, blastic, pleomorphic, and small cell subtypes of MCL. The dots represent the mean value within each class, and the bars represent the standard error of that mean estimate.
B: Kaplan-Meier plots of overall survival of patients in different histological MCL subtypes.
Cancer Cell 2003 3, DOI: ( /S (03)00028-X)

5. Figure 4
Relationship between cyclin D1 expression, proliferation, and survival in MCL
A: Relative cyclin D1 mRNA expression of the coding region (measured by quantitative RT-PCR, upper panel) and of the 3′ UTR (measured by DNA microarray analysis). The 92 cyclin D1-positive MCL cases are ordered according to their proliferation signature average (lower panel). The cyclin D1 expression is depicted over a 9-fold range, whereas the proliferation signature expression is depicted over a 4-fold range.
B: Histogram of cyclin D1 3′ UTR levels. Shown is a cutpoint that divides the MCL cases into a “3′ UTR low” group (17 cases) and a “3′ UTR high” group (75 cases).
C: Level of cyclin D1 coding region mRNA in the “3′ UTR low” and “3′ UTR high” groups of MCL. The dots represent the mean value within each class, and the bars represent the standard error of that mean estimate.
D: Proliferation signature averages of MCL cases in the “3′ UTR low” and “3′ UTR high” groups of MCL. The dots represent the mean value within each class, and the bars represent the standard error of that mean estimate.
E: Kaplan-Meier estimates of overall survival according to the level of cyclin D1 coding region mRNA expression.
F: Kaplan-Meier plot of overall survival according to cyclin D1 3′UTR expression.
G: The cyclin D1 locus: alternative 3′ polyadenylation sites can result in the expression of a short (1.7 kb) and a long (4.5 kb) cyclin D1 mRNA.
Cancer Cell 2003 3, DOI: ( /S (03)00028-X)

6. Figure 5 Deletions of INK4a/ARF, ATM, and p53 loci in MCL
A: Genomic loss of one or both alleles of the INK4a/ARF, ATM, and p53 loci as measured by quantitative PCR. MCL cases are ordered by their proliferation signature averages, and deletions are indicated by yellow squares. Black squares indicate wild-type configuration of the genomic loci, and gray squares indicate missing data. BMI-1 expression is depicted over a 9-fold range.
B: Influence of INK4a/ARF locus deletion on overall survival.
Cancer Cell 2003 3, DOI: ( /S (03)00028-X)